BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/14/2020 11:33:23 AM | Browse: 1295 | Download: 3050
Publication Name World Journal of Gastroenterology
Manuscript ID 56866
Country Netherlands
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Meta-Analysis
Article Title Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
Manuscript Source Unsolicited Manuscript
All Author List Mohammadreza Abdollahi, Neda Khalilian Ekrami, Morteza Ghojazadeh, H Marike Boezen, Mohammadhossein Somi and Behrooz Z Alizadeh
ORCID
Author(s) ORCID Number
Mohammadreza Abdollahi http://orcid.org/0000-0003-0455-4206
Neda Khalilian Ekrami http://orcid.org/0000-0003-3646-3106
Morteza Ghojazadeh http://orcid.org/0000-0002-9946-9452
H Marike Boezen http://orcid.org/0000-0002-4320-1481
Mohammadhossein Somi http://orcid.org/0000-0002-0770-9309
Behrooz Z Alizadeh http://orcid.org/0000-0002-1415-8007
Funding Agency and Grant Number
Corresponding Author Mohammadreza Abdollahi, MD, PhD, Doctor, Doctor, Department of Epidemiology, University of Groningen, Hanzeplein1, Groningen 9700 RB, Netherlands. m.abdollahi@umcg.nl
Key Words Autoimmune hepatitis; Efficacy; Grading of Recommendations Assessment, Development and Evaluation approach; Systematic review; Meta-analysis; Second-line
Core Tip There is no consensus in the literature on which second-line treatment is superior in autoimmune hepatitis (AIH). This is the first systematic review and meta-analysis to compare the efficacy and safety of tacrolimus and mycophenolate mofetil (MMF) as second-line treatments in AIH. We also evaluated the quality of evidence for adding to the clinical guidelines for routine practice. We conclude that tacrolimus and MMF are considered effective for patients who are non-responders or intolerant to first-line treatment, but the quality of evidence is not high and it is questionable if these results should be added to clinical guidelines for AIH.
Publish Date 2020-10-14 11:33
Citation Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910
URL https://www.wjgnet.com/1007-9327/full/v26/i38/5896.htm
DOI https://dx.doi.org/10.3748/wjg.v26.i38.5896
Full Article (PDF) WJG-26-5896.pdf
Full Article (Word) WJG-26-5896.docx